

UnitedHealthcare, Inc. ("UHC") Proprietary and Confidential Information: The information contained in this document is confidential, proprietary and the sole property of UHC. The recipient of this information agrees not to disclose or use it for any purpose other than to facilitate UHC's compliance with applicable State Medicaid contractual requirements. Any other use or disclosure is strictly prohibited and requires the express written consent of UHC.



Gynecomastia Surgery (for Louisiana Only)

Policy Number: CS051LA.~~JK~~

Effective Date: ~~November 1, 2022~~ TBD

[Instructions for Use](#)

Table of Contents	Page
Application	1
Coverage Rationale	1
Definitions	2
Applicable Codes	3
Description of Services	4
Clinical Evidence	4
U.S. Food and Drug Administration	8
References	8
Policy History/Revision Information	10
Instructions for Use	10

Application

This Medical Policy only applies to the state of Louisiana.

Coverage Rationale

A mastectomy for treatment of [Benign Gynecomastia](#) for a male member under age 18 is considered reconstructive and medically necessary when all the following criteria are met:

- Gynecomastia or breast enlargement with moderate to severe chest pain ~~that is~~ causing a [Functional or Physical Impairment](#). The inability to participate in athletic events, sports, or social activities is not considered to be a functional or physical, or physiological impairment.
- Persistent gynecomastia after cessation of prescribed medications and appropriate screening(s) of non-prescription and/or recreational drugs or substances that have a known side effect of gynecomastia (examples include, but are not limited to the following: testosterone, marijuana, asthma drugs, phenothiazines, anabolic steroids, ~~cimetidine~~ [cimetidine](#), and calcium channel blockers).
- The breast enlargement must be present for at least ~~two~~ 2 years, and appropriate evaluation of medical causes with supporting laboratory testing has been normal. If so, lab tests ~~which~~ might include, but are not limited to the following must be performed:
 - Hormone testing (e.g., beta-human chorionic gonadotropin, estradiol, follicle-stimulating hormone, luteinizing hormone, prolactin, testosterone)
 - Liver enzymes
 - Serum creatinine
 - Thyroid function studies

UnitedHealthcare, Inc. ("UHC") Proprietary and Confidential Information: The information contained in this document is confidential, proprietary and the sole property of UHC. The recipient of this information agrees not to disclose or use it for any purpose other than to facilitate UHC's compliance with applicable State Medicaid contractual requirements. Any other use or disclosure is strictly prohibited and requires the express written consent of UHC.

Mastectomy for treatment of Benign Gynecomastia for a male member age 18 and over is considered reconstructive and medically necessary when all the following criteria are met:

- Discontinuation of medications, nutritional supplements, and non-prescription medications or substances
(~~examples~~Examples include, but are not limited to the following: testosterone, marijuana, asthma drugs, phenothiazines, anabolic steroids, ~~cimetidine~~ cimetidine, and calcium channel blockers) that have a known side effect of gynecomastia or breast enlargement and the breast size did not regress after discontinuation of use as appropriate.
- Glandular breast tissue is the primary cause of gynecomastia as opposed to fatty deposits (pseudo gynecomastia) and is documented on physical exam and/or mammography.
- Gynecomastia or breast enlargement with moderate to severe chest pain ~~that is~~ causing a Functional or Physical Impairment. The inability to participate in athletic events, sports, or social activities is not considered to be a functional or physical, or physiological impairment.
- Appropriate evaluation of medical causes with supporting laboratory testing has been normal. If so, Lab tests ~~which~~ might include, but are not limited to the following must be performed:
 - o Hormone testing (e.g., beta-human chorionic gonadotropin, follicle-stimulating hormone, estradiol, luteinizing hormone, prolactin, testosterone)
 - o Liver enzymes
 - o Serum creatinine
 - o Thyroid function studies

Note: Regardless of age, if a tumor or neoplasm is suspected, a breast ultrasound and/or mammogram may be performed. As indicated, a breast biopsy may also be performed.

Definitions

Check the definitions within the federal, state, and contractual requirements that supersede the definitions below.

Benign Gynecomastia: Gynecomastia is defined as a unilateral or bilateral persistent benign mammary gland enlargement in men. Typically, true gynecomastia presents with a solid tissue mass palpable below the nipple-areolar complex. Malignant changes such as male mammary carcinoma must always be ruled out.⁸ There are numerous causes of gynecomastia. One cause is noted to be the imbalance of female to male hormones which triggers the onset of the disease. Endogenous causes may be hyperthyroidism, chronic liver disease, primary or secondary gonadal failure, androgen resistance syndromes, medication and drug abuse. A series of heart or hypertension medications can also trigger gynecomastia. The prevalence of asymptomatic gynecomastia is up to 65% and true gynecomastia must be distinguished from pseudo-gynecomastia.⁹ This condition can cause significant clinical manifestations when the excessive breast weight adversely affects the supporting structures of the shoulders, neck, and trunk. Depending on the underlying cause, the therapy of gynecomastia may be conservative or surgical (LCDed - cosmetic and reconstructive surgery, 2021).

American Society of Plastic Surgeons' gynecomastia scale (ASPS, 2015):

- Grade II: Moderate breast enlargement exceeding areola boundaries with edges that are indistinct from the chest.

UnitedHealthcare, Inc. ("UHC") Proprietary and Confidential Information: The information contained in this document is confidential, proprietary and the sole property of UHC. The recipient of this information agrees not to disclose or use it for any purpose other than to facilitate UHC's compliance with applicable State Medicaid contractual requirements. Any other use or disclosure is strictly prohibited and requires the express written consent of UHC.

- Grade III: Moderate breast enlargement exceeding areola boundaries with edges that are indistinct from the chest with skin redundancy present.
- Grade IV: Marked breast enlargement with skin redundancy and feminization of the breast

~~The development of abnormally large breasts in males. It is related to the excess growth of breast tissue (glandular) rather than excess fat tissue. (In most cases, breast enlargement and/or Benign Gynecomastia spontaneously resolves by age 18, making treatment unnecessary. Gynecomastia during puberty is not uncommon, and in 90% of cases regresses within three years of onset) (Ansstas, Ansstas, & Griffing, 2022).~~

Congenital Anomaly: A physical developmental defect is present at the time of birth and is identified within the first twelve months of delivery (COC, 2018). (Behrman et al. 2011).

Cosmetic Procedures: Procedures or services that change or improve appearance without significantly improving physiological function (COC, 2018).

Functional or Physical Impairment: A functional or physical, or physiological impairment causes deviation from the normal function of a tissue or organ. This results in a significantly limited, impaired, or delayed capacity to move, coordinate actions, or perform physical activities and is exhibited by difficulties in one or more of the following areas: physical and motor tasks, + independent movement, + performing basic life functions.

Reconstructive Procedures: Reconstructive Procedures when the primary purpose of the procedure is either of the following:

- Treatment of a medical condition
- Improvement or restoration of physiologic function
-

Reconstructive Procedures include surgery or other procedures ~~which are~~ related to an injury, ssickness, or Congenital Anomaly. The primary result of the procedure is not a changed or improved physical appearance.

Procedures that correct an anatomical Congenital Anomaly without improving or restoring physiologic function are considered Cosmetic Procedures. The fact that you may suffer psychological consequences or socially avoidant behavior due to as a result of an injury, ssickness or Congenital Anomaly does not classify surgery (or other procedures done to relieve such consequences or behavior) as a reconstructive procedure (COC, 2018).

Applicable Codes

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by federal, state, or contractual requirements and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

UnitedHealthcare, Inc. ("UHC") Proprietary and Confidential Information: The information contained in this document is confidential, proprietary and the sole property of UHC. The recipient of this information agrees not to disclose or use it for any purpose other than to facilitate UHC's compliance with applicable State Medicaid contractual requirements. Any other use or disclosure is strictly prohibited and requires the express written consent of UHC.

Note: Coding for suction lipectomy is addressed in the Medical Policy titled Panniculectomy and Body Contouring Procedures (for Louisiana Only).

CPT Code	Description
19300	Mastectomy for gynecomastia

CPT® is a registered trademark of the American Medical Association

Description of Services

Gynecomastia is a benign proliferation of glandular breast tissue in men. Physiologic gynecomastia is common in newborns, adolescents, and older men. Treatment is directed at minimizing emotional distress and physical discomfort. Nonphysiologic gynecomastia may be caused by chronic conditions including but not limited to cirrhosis, hypogonadism, and renal insufficiency; use of medications, supplements, or illicit drugs; and, rarely, tumors. Discontinuing using ~~use of~~ contributing medications and treating underlying diseases is the standard of practice. Medications, such as estrogen receptor modulators, and surgery, have a role in treating gynecomastia in select patients. Mastectomy is ~~refers to the~~ surgical removal of glandular breast tissue through an open incision or, more recently, through minimally endoscopic techniques. Cases considered severe may require ~~that are considered severe may requires~~ larger incisions (Dickson, 2012).

Clinical Evidence

Innocenti and associates (2022) performed a systematic review of the literature related to incidences of complications for different approaches in gynecomastia correction. In total, 94 articles were obtained consisting of 7294 individuals being analyzed. Three groups were created: aspiration techniques, consisting of 874 individuals (11.98%); surgical excision techniques, consisting of 2764 individuals (37.90%); and combined techniques, consisting of 3656 individuals (50.12%). The notable complications for each group totaled 1407. In the surgical excision techniques group, there were 847 (30.64%), 130 (14.87%) in the aspiration techniques group, and 430 (11.76%) in the combined techniques group. The authors concluded that the combined use of surgical excision and aspiration techniques reduces the rate of complications compared to that of the surgical excision alone; however, the lack of unique classification and presence of several surgical methods represents a bias in the literature review (Level of Evidence III).

In 2021, Trinchieri et al. conducted a systematic review and meta-analysis of randomized clinical trials concerning treatment-related gynecomastia for individuals taking spironolactone, antiandrogens, 5 alpha-reductase inhibitors, lipid-lowering, and psychotropic drugs through a systematic review and meta-analysis of randomized clinical trials. For men receiving antiandrogens, there was an increased risk of gynecomastia (OR = 17.38, 95% CI: 11.26 to 26.82; 6 trials, 9599 participants) and 5 alpha-reductase inhibitors compared to controls (OR = 1.77, 95% CI: 1.53 to 2.06; 7 series out of 6 trials, 34860 participants). Compared to controls, using spironolactone in mixed-gender populations were considered to have substantially higher odds of having gynecomastia (OR = 8.39, 95% CI: 5.03 to 13.99; 14 trials, 3745 participants). There was a noteworthy variance in the odds of having gynecomastia in an evaluation between risperidone and quetiapine (OR = 4.32, 95% CI: 1.31 to 14.27; 3 trials, 343 participants), however; no placebo-controlled trials concentrating on the risk of gynecomastia for individuals taking antipsychotic drugs was obtainable. Antiandrogens, 5 alpha-reductase inhibitors, and spironolactone are associated with an increased risk of developing gynecomastia.

UnitedHealthcare, Inc. ("UHC") Proprietary and Confidential Information: The information contained in this document is confidential, proprietary and the sole property of UHC. The recipient of this information agrees not to disclose or use it for any purpose other than to facilitate UHC's compliance with applicable State Medicaid contractual requirements. Any other use or disclosure is strictly prohibited and requires the express written consent of UHC.

Holzmer and colleagues., (2020) conducted a comprehensive review of the literature regarding the surgical management of gynecomastia to analyze surgical practice patterns and trends pertaining to the grade and severity of gynecomastia. The primary data points were the complication rate, including hematoma, seroma, infection, necrosis, drain use, gynecomastia grade, and surgical intervention. A total of 1112 individuals received surgical treatment for gynecomastia, with the most used technique being skin-sparing mastectomy with or without liposuction, followed by mastectomy with skin reduction. The most common complication noted was hematoma formation which comprised 5.8% of complications, followed by seroma, 2.4%. Those who routinely utilized drain placement demonstrated a higher rate of hematoma/seroma formation (9.78% vs. 8.36%; P= 0.0051). However, a limitation is a large discrepancy in the percentage of grade III individuals found in each group (50.23% vs. 4.36%; P=0.0000). The authors concluded that there is a wide range of surgical techniques for treating gynecomastia. No definitive, universally accepted algorithm exists showing the ideal surgical approach for treating gynecomastia based on severity. An individualized approach based on gynecomastia grade and individual preference should assist the surgeon in providing the best outcomes.

A randomized controlled trial was conducted by Hasan in 2019 to compare operative techniques; modified Benelli technique vs. subcutaneous mastectomy using periareolar incision. Participants were divided into two groups regarding their surgical technique to carry out the trial. Group A consisted of 75 individuals undergoing surgical treatment with subcutaneous mastectomy using periareolar incision, and group B included 75 individuals being managed by the modified Benelli technique. The trial results uncovered that the modified Benelli technique; had a lower operating time and retained a cosmetically acceptable position of the areola; however, there was much pleating of the skin compared to the periareolar incision. The authors concluded that the modified Benelli technique offers a reasonably simple surgical approach with an aesthetically positive outcome to treat gynecomastia with a low rate of complications and recurrences.

In a 2018 systematic review, Sollie sought to identify the psychological domains affected by gynecomastia and the effect of surgical treatment on these. Primary outcomes consisted of quality of life and several psychological domains after surgical treatment for gynecomastia, specifically, vitality, emotional discomfort, limitations due to physical aspects, and limitations due to pain. The author concluded that the impact of surgical treatment for gynecomastia is beneficial for several of the psychological domains and restrictions due to pain; however, the current level of evidence on the subject is low, requiring future studies that examine the impact of the surgical intervention for gynecomastia on psychological domains are necessary.

In 2018, Nuzzi and colleagues studied the effect of surgical treatment for gynecomastia on the quality of life in adolescents through surveys. The surveys were distributed to adolescents ages 12-21 with gynecomastia and male controls. The surveys consisted of the short-form 36v2 (SF-36), Rosenberg Self-Esteem Scale (RSES), and Eating-Attitudes Test-26. Surveys were completed at baseline, postoperatively, six months, one year, three- and five-year follow-ups. Participants in the study were 64 unaffected male controls. For the five SF-36 domains: general health, vitality, social functioning, role-emotional, and mental health, the individuals with gynecomastia scored significantly worse than controls and on the RSES. Postoperative improvements were noted in the scores of the RSES and the four SF-36 domains physical functioning, role-physical, bodily pain, and social functioning. Gynecomastia subjects scored similarly to controls in all SF-36 domains and the RSES postoperatively. Limitations in the study consist of the need for follow-up BMI

UnitedHealthcare, Inc. ("UHC") Proprietary and Confidential Information: The information contained in this document is confidential, proprietary and the sole property of UHC. The recipient of this information agrees not to disclose or use it for any purpose other than to facilitate UHC's compliance with applicable State Medicaid contractual requirements. Any other use or disclosure is strictly prohibited and requires the express written consent of UHC.

data and the lack of comparison between baseline physical activity and the SF-36 survey, which confirms that the subjects have the potential for physical activity. Additional limitations include the sample size, risk for bias, and recruitment from a single, large tertiary care facility. The authors concluded that surgical treatment of gynecomastia improves the quality of life for adolescents, especially those overweight individuals with severe gynecomastia, and measurable improvements in psychosocial and physical functioning are evident.

Zavlin D et al. (2017) performed a retrospective analysis from ~~the databases of the~~ American College of Surgeons National Surgical Quality Improvement Program databases for adults and pediatrics to produce two cohorts that underwent surgical repair of gynecomastia. The study's goal ~~goal of the study~~ was to assess patient demographics, surgical outcomes, and complications. A total of 1787 individuals were identified, 204 pediatric and 1583 adult males. The mMean ages were 15.8 and 39.6, respectively. The results demonstrated low surgical (3.9 and 1.9%) and medical (0.0 and 0.3%) complications within the standardized 30-day postoperative period. Children and adolescents, however, required double mean operative times compared to adults (111.3 vs. 56.7 min). The authors concluded that operative gynecomastia treatment remains a safe modality across all age groups.

~~Hayes (2010) published a health technology assessment for Mastectomy for gynecomastia. This assessment was based on 7 retrospective studies that included more than 50 individuals and 1 small prospective case series with 36 individuals. In the largest retrospective study by Petty et al. (2010) the efficacy and safety of 4 surgical procedures were compared involving 227 individuals. The participants were divided into 4 groups. Each group underwent a different surgical procedure. Mean follow-up was 6 months. Despite positive findings, weaknesses of this study include its retrospective design, loss to follow-up, and lack of blind assessment of the results. Evaluation of the other retrospective studies and small prospective case series resulted in similar conclusions. However, the evidence suggests that surgery for gynecomastia is an appropriate option for carefully selected patients with symptomatic persistent disease who have not responded to medical therapy, when surgery is performed by a surgeon with experience in the selected technique, and when tissue is submitted for histopathological examination.~~

~~In a prospective randomized clinical trial, Saariniemi et al. (2007) investigated the effectiveness of reduction mammoplasty for the treatment of symptomatic breast hypertrophy. 82Eighty-two individuals participated in the study. 40Forty individuals were part of the operative group, and 42 individuals to the nonoperative group. Both groups were examined at 0 and 6 months using a short form 36 quality of life questionnaire, 15D quality of life questionnaire, and the Finnish Pain Questionnaire, and analysis of covariance was applied for instrumental data comparison. 29Twenty-nine participants in the operative group and 35 participants in the nonoperative group completed the study. The mean age was 46 years. Although the study recommended resulted in the recommendation that reduction of mammoplasty results in a significant improvement inof quality of life and a decrease in pain and breast-associated symptoms, it also noted that future studies should be focused on the patient on participant selection and justification of the treatment by comparing with other approved treatments.~~

Clinical Practice Guidelines

American Society of Andrology and European Academy of Andrology (ASA/EAA)

- The existence of an underlying pathology should be considered for gynecomastia in adulthood. The recommendation is to identify an apparent cause for gynecomastia in adulthood, including the use of medication recognized to be related to gynecomastia, which should not preclude a detailed investigation (moderate quality).
- Initial screening is suggested to rule out lipomastia, apparent breast cancer, or testicular cancer, which may be completed by a general practitioner or another clinical professional (very low-quality).
- In those cases where a comprehensive diagnostic workup is necessary, it should be accomplished by a specialist (very low-quality).
- The individual's medical history is recommended to incorporate information involving the onset and duration of gynecomastia, sexual development and function, and administration or abuse of substances associated with gynecomastia (moderate quality).
- The physical examination should identify signs of under-virilization or systemic disease (high quality).
- Breast examination should confirm the presence of palpable glandular tissue to differentiate from lipomastia (pseudo-gynecomastia) and rule out the suspicion of malignant breast tumor (high quality).
- The physical examination should involve the assessment of the genitalia to rule out the presence of a palpable testicular tumor and to identify testicular atrophy (high quality).
- Genitalia examination assisted by a testicular ultrasound, as the detection of a testicular tumor by palpation has low sensitivity (low quality).
- A set of evaluations may incorporate T, E2, SHBG, LH, FSH, TSH, prolactin, hCG, AFP, and liver adrenal function tests (low quality).
- Breast imaging may assist when the clinical examination is vague (low quality).
- If the clinical picture is suspect of a malignant lesion, a core needle biopsy should be completed (low quality).
- Watchful waiting should occur after treatment of underlying pathology or cessation of the administration/abuse of substances connected with gynecomastia (low quality).
- Treatment should be offered exclusively to men with established testosterone insufficiency (moderate quality).
- The use of selective estrogen receptor modulators (SERMs), aromatase inhibitors (Ais), or non-aromatizable androgens for treating gynecomastia, in general, is NOT recommended (low quality).
- Surgical treatment is only for individuals with persistent gynecomastia, which does not regress naturally or through subsequent medical therapy. The magnitude and type of surgery depend on the size of breast enlargement and the quantity of adipose tissue (low quality) (Kanakakis et al., 2019).

American Society of Plastic Surgeons (ASPS)

The 2016 ASPS's recommendations for gynecomastia surgery for adolescents:

- Unilateral or bilateral grade II or grade III gynecomastia present (per modified McKinney and Simon, Hoffman, and Kohn scales)

UnitedHealthcare, Inc. ("UHC") Proprietary and Confidential Information: The information contained in this document is confidential, proprietary and the sole property of UHC. The recipient of this information agrees not to disclose or use it for any purpose other than to facilitate UHC's compliance with applicable State Medicaid contractual requirements. Any other use or disclosure is strictly prohibited and requires the express written consent of UHC.

- Continues more than one year following pathological sources ruled out
 - Continues after six months of failed medical treatment for pathological gynecomastia
 - Unilateral or bilateral grade IV gynecomastia present (per modified McKinney and Simon, Hoffman, and Kohn scales)
 - Continues more than six months following pathological reasons ruled out
 - Continues after six months of failed medical treatment for pathological gynecomastia
 - Pain and discomfort due to the distention and stiffness from the hypertrophied breast
Gynecomastia may cause considerable psychological anguish, particularly in adolescents struggling with matters associated with sexual identity and self-image.
- The ASPS's recommendations for gynecomastia surgery for adults:
- Breast biopsy is suggested when malignancy is presumed
 - Unilateral or bilateral grade III or IV gynecomastia present (per modified McKinney and Simon, Hoffman, and Kohn scales)
 - Continues for more than 3 to 4 months following pathological reasons ruled out
 - Continues after 3 to 4 months of failed medical therapy for pathological gynecomastia
 - Pain and discomfort due to the distention and stiffness from the hypertrophied breast (French, 2016).

U.S. Food and Drug Administration (FDA)

This section is to be used for informational purposes only. FDA approval alone is not a basis for coverage.

Surgeries for the treatment of gynecomastia are procedures and therefore not regulated by the FDA. Refer to the following website for additional information:

<http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm>.

(Accessed— February 8, 2023 January 25, 2022)

References

Cosmetic procedures. (2022). American Society of Plastic Surgeons.
<https://www.plasticsurgery.org/cosmetic-procedures> Accessed: February 9, 2023.

Dickson G. Gynecomastia. Am Fam Physician. 2012 Apr 1;85(7):716-22.

Enlarged breasts in men (gynecomastia) – symptoms and causes – mayo clinic. (2014). Mayo clinic. <https://www.mayoclinic.org/diseases-conditions/gynecomastia/symptoms-causes/syn-20351793>. Accessed: February 8, 2023. Dickson, Gretchen, Gynecomastia, University of Kansas School of Medicine, April 1, 2012, Volume 85, Number 7.

Expert Panel on Breast Imaging: Niell BL, Lourenco AP, Moy L, et al. ACR Appropriateness Criteria® Evaluation of the symptomatic male breast. J Am Coll Radiol. 2018 Nov;15(11S):S313-S320. [https://www.jacr.org/article/S1546-1440\(18\)31159-1/fulltext](https://www.jacr.org/article/S1546-1440(18)31159-1/fulltext). Accessed February 8, 2023.

French, C. (2016). Gynecomastia icc [PDF]. American Society of Plastic Surgeons. https://www.plasticsurgery.org/documents/Health-Policy/Positions/Gynecomastia_ICC.pdf Accessed: February 9, 2023.

UnitedHealthcare, Inc. ("UHC") Proprietary and Confidential Information: The information contained in this document is confidential, proprietary and the sole property of UHC. The recipient of this information agrees not to disclose or use it for any purpose other than to facilitate UHC's compliance with applicable State Medicaid contractual requirements. Any other use or disclosure is strictly prohibited and requires the express written consent of UHC.

~~Hayes, Health Technology Assessment, Mastectomy for Gynecomastia, Jul 12, 2012. Archived Aug 5, 2013.~~

~~Holzmer SW, Lewis PG, Landau MJ, et al. Surgical management of gynecomastia: a comprehensive review of the literature. Plast Reconstr Surg Glob Open. 2020 Oct 29;8(10):e3161.~~

~~Kanakakis GA, Nordkap L, Bang AK, et al. EAA clinical practice guidelines-gynecomastia evaluation and management. Andrology. 2019 Nov;7(6):778-793.
<https://onlinelibrary.wiley.com/doi/full/10.1111/andr.12636> Accessed: February 8, 2023.~~

~~LedCD - cosmetic and reconstructive surgery (135090). (2021). Centers for Medicare & Medicaid Services. <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?LCDId=35090> Accessed: February 23, 2023.~~

~~Leung AKC, Leung AAC. Gynecomastia in Infants, Children, and Adolescents. Recent Pat Endocr Metab Immune Drug Discov. 2017;10(2):127-137.~~

~~Narula HS, Carlson HE. Gynecomastia. Endocrinol Metab Clin North Am. 2007 Jun;36(2):497-519.~~

~~Nuzzi LC, Firriolo JM, Pike CM, The effect of surgical treatment for gynecomastia on quality of life in adolescents. j adolesc health. 2018 Dec;63(6):759-765.~~

~~Reconstructive procedures. (2022). American Society of Plastic Surgeons.
<https://www.plasticsurgery.org/reconstructive-procedures> Accessed: February 9, 2023.~~

~~Saariniemi KM, Keranen UH, Salminen-Peltola PK, et al. Reduction mammoplasty is effective treatment according to two quality of life instruments. A prospective randomised clinical trial. J Plast Reconstr Aesthet Surg. 2008 Dec;61(12):1472-8.~~

~~Sansone A, Romanelli F, Sansone M, et al. Gynecomastia and hormones. Endocrine. 2017 Jan;55(1):37-44. Gynecomastia and hormones. Sansone A et al. Endocrine. 2017.~~

~~Sollie M. Management of gynecomastia-changes in psychological aspects after surgery-a systematic review. Gland Surg. 2018 Aug;7(Suppl 1):S70-S76.~~

~~Trinchieri A, Perletti G, Magri V, et al. Drug-induced gynecomastia: A systematic review and meta-analysis of randomized clinical trials. Arch Ital Urol Androl. 2021 Dec 21;93(4):489-496.~~

~~[UnitedHealthcare Insurance Company Generic Certificate of Coverage 2018.](#)~~

~~Gynecomastia in Infants, Children, and Adolescents. Leung AKC et al. Recent Pat Endocr Metab Immune Drug Discov. 2017.~~

~~Hayes, Health Technology Assessment, Mastectomy for Gynecomastia, Jul 12, 2012. Archived Aug 5, 2013.~~

~~Mayo Clinic: Diseases and Conditions. Gynecomastia (enlarged breasts in men). January 22, 2014.~~

~~Narula HS, Carlson HE. Gynecomastia. Endocrinol Metab Clin North Am. 2007/36:497-519. NIH Medline Plus. Updated December 19, 2014.~~

~~Saariniemi KM, Keranen UH, Salminen-Peltola PK et al. Reduction mammoplasty is effective treatment according to two quality of life instruments. A prospective randomised clinical trial. Journal of Plastic, Reconstructive & Aesthetic Surgery, 2008-12-01, Volume 61, Issue 12.~~

~~Zavlin D, Jubbal KT, Friedman JD, et al. Complications and outcomes after gynecomastia surgery: Analysis of 204 pediatric and 1583 adult cases from a national multi-center database. Aesthetic Plast Surg. 2017 Aug;41(4):761-767.~~

UnitedHealthcare, Inc. ("UHC") Proprietary and Confidential Information: The information contained in this document is confidential, proprietary and the sole property of UHC. The recipient of this information agrees not to disclose or use it for any purpose other than to facilitate UHC's compliance with applicable State Medicaid contractual requirements. Any other use or disclosure is strictly prohibited and requires the express written consent of UHC.

Policy History/Revision Information

Date	Summary of Changes
<u>TBD</u>	<p><u>Definitions</u></p> <ul style="list-style-type: none"> • Updated definition of: <ul style="list-style-type: none"> ○ <u>Benign Gynecomastia</u> • <u>Congenital Anomaly</u> ○ <u>Reconstructive Procedures</u> <p><u>Supporting Information</u></p> <ul style="list-style-type: none"> • Updated <u>Clinical Evidence</u> and <u>References</u> sections to reflect the most current information • Archived previous policy version CS051IA.J

Instructions for Use

This Medical Policy provides assistance in interpreting UnitedHealthcare standard benefit plans. When deciding coverage, the federal, state or contractual requirements for benefit plan coverage must be referenced as the terms of the federal, state or contractual requirements for benefit plan coverage may differ from the standard benefit plan. In the event of a conflict, the federal, state or contractual requirements for benefit plan coverage govern. Before using this policy, please check the federal, state or contractual requirements for benefit plan coverage. UnitedHealthcare reserves the right to modify its Policies and Guidelines as necessary. This Medical Policy is provided for informational purposes. It does not constitute medical advice.

UnitedHealthcare may also use tools developed by third parties, such as the InterQual® criteria, to assist us in administering health benefits. The UnitedHealthcare Medical Policies are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.